Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/apt.18104 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Trifluridine-tipiracil plus bevacizumab in refractory metastatic colorectal cancer].
Bull Cancer
December 2024
Département d'oncologie digestive, hôpital européen George-Pompidou, 20, rue Leblanc, 75015 Paris, France.
Defining failure of endoluminal biliary drainage in the era of endoscopic ultrasound and lumen apposing metal stents.
World J Gastroenterol
August 2024
Department of Clinical Sciences, Tilman J. Fertitta Family College of Medicine, University of Houston, Houston, TX 77204, United States.
The role of endoscopy in pathologies of the bile duct and gallbladder has seen notable advancements over the past two decades. With advancements in stent technology, such as the development of lumen-apposing metal stents, and adoption of endoscopic ultrasound and electrosurgical principles in therapeutic endoscopy, what was once considered endoscopic failure has transformed into failure of an approach that could be salvaged by a second- or third-line endoscopic strategy. Incorporation of these advancements in routine patient care will require formal training and multidisciplinary acceptance of established techniques and collaboration for advancement of experimental techniques to generate robust evidence that can be utilized to serve patients to the best of our ability.
View Article and Find Full Text PDFComparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphoma.
J Hematol Oncol
August 2024
Hackensack Meridian School of Medicine, Nutley, NJ, USA.
Article Synopsis
- - The study evaluated the effectiveness of epcoritamab for treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL) by comparing it to other therapies used after at least two prior treatments, using advanced statistical methods to ensure fair comparisons.
- - Epcoritamab showed significantly better response and overall survival rates than traditional chemoimmunotherapy (CIT) and other novel therapies, such as polatuzumab-based and tafasitamab-based regimens.
- - However, there were no significant differences in response or survival rates when comparing epcoritamab to CAR T-cell therapies in patients with relapsed/refractory large B-cell lymphoma.
Treatment-free remission after third-line therapy with asciminib in chronic myeloid leukemia with an atypical e19a2 BCR::ABL1 transcript and T315I mutation.
Leukemia
September 2024
Klinik für Innere Medizin II, Universitätsklinikum Jena, Comprehensive Cancer Center Central Germany, Campus Jena, Jena, Germany.
Letter: Third-line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions-Authors' reply.
Aliment Pharmacol Ther
July 2024
Gastroenterology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Universidad Autónoma de Madrid (UAM), Madrid, Spain.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!